57 results about "Sustained-Release Preparations" patented technology

The invention relates to the technical field of pharmaceutical preparations, in particular to a solid dispersion-based sustained-release drug composite carrier as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out synergistic spray drying on double polymers (hydroxypropyl methylcellulose acetate succinate and polyvinylpyrrolidone-vinyl acetate copolymer) to form a solid dispersion; compounding with mesoporous silica and calcium silicate for localization, and spraying ethanol to activate pores; calcium stearate and magnesium stearate are sequentially added for lubrication; prefabricating a sustained-release skeleton master batch; and finally, mixing, rolling and forming. According to the method, through hierarchical structural design, the drug stability, the powder fluidity and the release controllability are remarkably improved, the method is suitable for industrial production of the dihydroergoline mesylate sustained release preparation, and a release curve is smooth and reliable.

The invention discloses a muscle-bone regeneration sustained-release preparation for targeting knee joint cartilage and a preparation process thereof, the preparation is composed of a cartilage targeting peptide modified PLGA-hyaluronic acid composite nanoparticle sustained-release carrier, an active regeneration component, a biocompatible matrix and an anti-inflammatory component, nanoparticles are prepared by a multiple emulsion solvent evaporation method, and targeting peptide is modified; the composite concentrated growth factors, stem cells and traditional Chinese medicine extracts have the functions of targeted enrichment, long-acting slow release, anti-inflammation and cartilage regeneration promotion, and can be used for knee joint cartilage defect repair.

The invention provides a drug sustained release preparation for inhibiting vascular intimal hyperplasia and a preparation method and application thereof, and belongs to the technical field of biological medicine and vascular surgery. The drug sustained release preparation for inhibiting vascular intimal hyperplasia comprises a temperature-sensitive high polymer material and an MRTF / SRF pathway inhibitor, the temperature-sensitive high polymer material is a Pluronic type triblock copolymer; and the effective component of the MRTF / SRF pathway inhibitor is CCG222740 or CCG203971. The invention further discloses a preparation method of the MRTF / SRF pathway inhibitor. The drug sustained release preparation for inhibiting the vascular intimal hyperplasia can continuously release the MRTF / SRF pathway inhibitor at a fixed point in the AVF and other vascular injury repair process, can reduce at least 50% of neointimal area and vascular intimal-intimal thickness, and effectively inhibits the intimal hyperplasia.

The application discloses a sustained-release preparation of indobufen and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The application relates to a sustained-release preparation of indobufen and a preparation method and application thereof. The preparation has the characteristics of stable sustained-release effect, high bioavailability, good drug-taking compliance and small side effect, and is suitable for the prevention and / or treatment of diseases such as ischemic cardiovascular diseases, ischemic cerebrovascular diseases and venous thrombosis.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The present application relates to microspheres having a physiologically active substance uniformly dispersed therein and sustained-release preparations containing the same. In the present application, microspheres are provided, which are microspheres having a physiologically active substance uniformly dispersed therein with a lactic acid / glycolic acid copolymer (PLGA) as a main component, characterized in that the average volume-based particle diameter of the microspheres is 1 μm or more and 150 μm or less, and no lump or pore of the physiologically active substance of 1.5 μm or more is present in the microspheres. The microspheres of the present application can appropriately control the initial release amount of the physiologically active substance and the release rate during the period thereafter, and continuously release the physiologically active substance in vivo for a certain period.

The application discloses an exosome sustained-release preparation and application thereof in treatment of tendon injury, and the sustained-release preparation takes a silk fibroin frozen sponge as a carrier, and the carrier is loaded with exosomes. The application provides the silk fibroin frozen sponge as the carrier of the exosomes, and the silk fibroin frozen sponge has good biocompatibility and biodegradability; the sustained release of the exosomes is realized by controlling a protein fiber network structure of the silk fibroin. The application utilizes the silk fibroin frozen sponge to release the exosomes in situ at a tendon injury site, so that a better tendon repair effect is achieved.

The invention relates to the technical field of breeding regulation and control of black goats, in particular to a hormone treatment method for inducing estrus synchronization of black goats, which comprises the following steps: placing a CIDR vaginal suppository containing 1.38-1.56 g of progesterone into the vagina of an ewe, and keeping for 12-14 days; 48 hours before the thrombus is removed, intramuscularly injecting a sustained release preparation of 330 IU follicle-stimulating hormone and 30% polyvinylpyrrolidone; when the thrombus is removed, intramuscularly injecting a mixed solution containing 330IU pregnant mare serum gonadotropin and 0.1 mg of cloprostenol; 24 hours after the thrombus is removed, 25 micrograms of luteinizing hormone is intravenously injected to release hormone A3; single-time artificial insemination is performed within 48-56 hours after injection, 0.5 ml of semen is left for each injection, and the number of effective sperms is not less than 1.5 * 10 < 8 >. By precisely regulating and controlling CIDR progesterone and multi-hormone stepped injection, the estrus synchronization rate of a group is larger than or equal to 95%, and the traditional synchronization bottleneck is broken through; insemination parameters are controlled and optimized management is carried out, each fetal live lamb is 2.5-3.0, and the breeding efficiency is improved; treatment is started 45-50 days after delivery, the lambing interval is 210 + / -10 days, and large-scale efficient breeding is assisted.

The invention provides a tamsulosin hydrochloride sustained release preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: spraying an ethanol water solution of tamsulosin hydrochloride on a mesoporous silica carrier, and drying to obtain a drug-containing carrier; mixing the drug-containing carrier, an auxiliary carrier, an adhesive and water, and carrying out wet granulation to obtain a drug-containing soft material; extruding and rounding the medicine-containing soft material to obtain a medicine-containing pellet core; coating the drug-containing pellet core with a coating solution to obtain a coated pellet core; the coating liquid comprises an enteric-coated material and a plasticizer; and mixing the coated pellet core with a lubricant to obtain the tamsulosin hydrochloride sustained release preparation. The tamsulosin hydrochloride sustained-release preparation prepared by the method is good in drug content stability, stable in main drug release, simple in process, high in controllability and suitable for industrial production.

The invention discloses a cat and dog gastrointestinal inflammation alleviator containing plant extracts and application of the cat and dog gastrointestinal inflammation alleviator, and relates to the field of pet health. The alleviator is prepared by compounding a plant extract component, a micro-ecological component, a functional auxiliary component and a carrier raw material, plant active components are purified by adopting an ultrasonic-assisted ethanol gradient elution combined membrane separation technology, and the problem of antagonism of a plant extract and probiotics is solved through microcapsule embedding and step-by-step compounding. The sustained-release preparation is prepared by combining sustained-release preparation forming and palatability optimization technologies. The traditional Chinese medicine composition can synergistically achieve the effects of resisting inflammation, repairing gastrointestinal mucosa, regulating intestinal flora and quickly stopping diarrhea, is suitable for preventing and treating acute and chronic enterogastritis of cats and dogs, and is good in palatability, high in stability, free of obvious toxic and side effects and convenient to administrate.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an arginine ibuprofen biphasic sustained release preparation and a preparation method thereof. Through a two-phase system of quick-release particles and slow-release particles, the problems that a traditional preparation takes effect slowly, is short in medicine effect and poor in taste are solved. Wherein the quick-release granules are prepared by mixing and granulating ibuprofen arginine, a filling agent, an adhesive and a natural flavoring agent, so that the effective blood concentration can be ensured to be reached within 15 minutes after the medicine is orally taken so as to quickly relieve pain, and the bad flavor of the medicine can be synchronously covered; the sustained-release granules are based on an ibuprofen arginine drug-loading core, the outer layer of the sustained-release granules is coated with a sustained-release film formed by a sustained-release agent and a plasticizer, and the effective blood concentration can be stably maintained for 6-8 hours, so that the medicine taking frequency is reduced, the sustained-release granules only need to be taken for 1-2 times every day, the medication compliance of a patient is greatly improved, and the sustained-release granules are suitable for clinical application. The traditional Chinese medicine composition is especially suitable for clinical scenes needing long-term or repeated analgesia such as chronic arthritis and postoperative pain, has excellent safety and practicability, and has a wide market application prospect.

A brivaracetam pharmaceutical composition contains an active pharmaceutical ingredient, a matrix forming agent, and a swelling agent. It has a sustained release effect and has a more flat release curve compared with a common gel skeleton sustained-release preparation, and thus achieves the purposes of reducing the release rate of the medicament, controlling the in vivo effective dosage of the medicament, stabilizing the blood concentration, reducing toxic and side effects and reducing the times of daily administration.

The invention relates to the technical field of biological medicines, in particular to application of biotin medicines and application of a biotin sustained release preparation. Biotin drugs are used for preparing drugs for promoting cartilage formation, retarding osteoarthritis progress and inhibiting cartilage loss, and can effectively relieve and treat osteoarthritis.

The invention discloses a preparation method of a traditional Chinese medicine composition for treating skin tinea, allergic dermatitis and acne, and relates to the field of pharmaceutical preparations, the extraction rate of gallic acid and ethyl gallate contained in total tannin in fructus chebulae flesh, fructus terminaliae billericae flesh and fructus chebulae immaturus is improved through an enzymolysis method, and the transfer rate of effective components of quercetin is improved through a boiling granulation technology; therefore, the effect of treating psoriasis of the composition is improved. By adopting a boiling granulation technology, the technical problems of long preparation period and high cost in the prior art are solved. The release speed of aloe in intestinal tracts is controlled by adopting a slow release technology, and the upper and lower limit content range of barbaloin is controlled to reduce the occurrence rate of adverse reactions of the composition. Meanwhile, butyl hydroxy anisd (BHA), butylated hydroxytoluene (BHT) and a citric acid system are adopted, so that the problems of PEO skeleton degradation, out-of-control drug release behavior and insufficient main drug stability of the barbaloin-PEO sustained release preparation are solved.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a 4-aminopyridine sustained release preparation and a preparation method thereof. The sustained release preparation comprises 4-aminopyridine, ethyl-beta cyclodextrin-calcium carbonate microspheres, a filler, an adhesive, a disintegrating agent and a lubricant. According to the sustained-release preparation, the sustained-release time can be prolonged, the medicine taking frequency is reduced, the content uniformity of the preparation is improved, meanwhile, the preparation process is improved, and stimulation to operators, environment control in a production workshop and equipment cost are reduced.

The invention relates to the technical field of sustained-release preparation, in particular to a microcrystalline sustained-release preparation and a preparation method thereof.The sustained-release preparation comprises a core composed of edaravone rodlike microcrystals and a shell composed of 2-4 double layers, the shell comprises at least one polyethylene glycol-polylysine copolymer inner layer, and the polyethylene glycol-polylysine copolymer inner layer is a polyethylene glycol-polylysine copolymer outer layer. And at least one outer layer of hyaluronic acid modified with a CD44 targeting peptide. The CD44 targeting peptide modified by the shell layer can specifically recognize a CD44 receptor on the surface of an inner ear hair cell, so that the binding efficiency of a preparation, a round window membrane and a target cell is remarkably improved, the diffusion of a drug to non-target tissues is reduced, and the local drug concentration is improved.

The application belongs to the technical field of microbial preparation, and specifically discloses a kind of SA-MPN encapsulated bacteriophage preparation and its preparation method and application, its preparation method includes the following steps: take bacteriophage cocktail concentrate, add tannic acid solution, FeCl3·6H2O solution, phosphate buffer solution, obtain metal phenolic aldehyde network encapsulated bacteriophage;Subsequently, CaCl2 solution and sodium alginate solution are added to the metal phenolic aldehyde network encapsulated bacteriophage in sequence, to obtain sodium alginate-metal phenolic aldehyde network-bacteriophage mixture microcapsules.The application adopts the above-mentioned SA-MPN encapsulated bacteriophage preparation and its preparation method and application, which can effectively protect bacteriophage from gastric acid, high temperature and ultraviolet stress, realize intestinal targeting and slow release, has high encapsulation efficiency, good stability, antioxidant activity, significant antibacterial effect on salmonella and high biological safety.

The invention relates to the technical field of pharmaceutical preparations, in particular to a goserelin sustained-release microsphere, a goserelin sustained-release microsphere, a preparation method thereof and a sustained-release preparation. The goserelin sustained release microsphere comprises a medicinal active ingredient goserelin and a polymer carrier lactide-glycolide copolymer, wherein the molar ratio of a lactic acid unit to a glycolic acid unit is 75: 25-95: 5. The goserelin sustained release microsphere and the sustained release preparation have the advantages of long drug release period, almost no hysteresis period and sustained and stable release in vivo.

The present application discloses a phenyl boronic acid compound, which contains a phenyl boronic acid group and a carbon-carbon double bond group, and the phenyl boronic acid group can be combined with glucose. The present application also discloses a polymer, which is obtained by free radical copolymerization of the above-mentioned phenyl boronic acid compound, a monomer containing A and an initiator in a solvent. The present application further discloses an insulin sustained-release preparation containing the above-mentioned polymer, which has different insulin release rates under different glucose concentrations, and can accelerate the release of insulin under a hyperglycemic environment to reduce blood glucose. The present application further discloses a preparation method of the above-mentioned insulin sustained-release preparation, which self-assembles the negatively charged insulin and the positively charged double-phenyl boronic acid modified polymer into the insulin sustained-release preparation through electrostatic interaction, and has the characteristics of high loading rate. The prepared insulin sustained-release preparation can release insulin, and the released insulin can bind to insulin receptors in the body to reduce blood glucose level.

The invention discloses a sustained release preparation based on composite carrier coated calcium peroxide, a preparation method and application, and belongs to the technical field of aquaculture substrate improvement, and the preparation method comprises the following steps: S1, adding a layered silicate clay mineral into water, heating and stirring, then adding an organosilane modifier for reaction, standing at constant temperature for a certain time, and filtering to obtain a filter cake; filtering to obtain activated layered silicate clay minerals; s2, pouring the activated layered silicate clay mineral obtained in the step S1 into a mixed aqueous solution of sodium alginate and food-grade white granulated sugar, stirring to obtain an activated montmorillonite-sodium alginate composite carrier solution, then adding calcium peroxide, and performing secondary stirring for a certain time to obtain a calcium peroxide-carrier mixed solution; and then introducing into an injector, dripping into normal-temperature deionized water to prepare small balls with a certain size, freezing, and drying in stages to obtain the sustained release preparation based on calcium peroxide wrapped by the composite carrier. The calcium peroxide loading capacity can be improved, and the calcium peroxide release period can be prolonged.

The invention provides a long-acting injection preparation based on an alpha-lipoic acid derivative and a preparation method and application thereof, and the preparation method of the long-acting injection preparation comprises the following steps: taking alpha-lipoic acid as a carboxylic acid donor and n-hexylamine as a primary amine donor, and carrying out reaction in a system of EDC and NHS to generate N-hexyl lipoic amide; n-hexyl lipoic amide and alpha-lipoic acid are dissolved in dimethyl sulfoxide according to the mass ratio of 1: 1 for a reaction, and the long-acting injection preparation is obtained. The long-acting injection preparation can realize in-situ phase change and drug long-acting slow release through solvent diffusion response, has good injectability and biocompatibility, can be used as a drug delivery carrier, and is used for long-term treatment of chronic metabolic diseases.

The invention relates to the technical field of data processing, and discloses a walnut disease grading prevention and control method and system and a storage medium. The method comprises the steps of collecting multi-band spectrum and temperature data of walnut trees to calculate disease characteristic indexes, constructing an orchard network according to inter-tree positions and propagation relations, inputting a graph convolutional network to extract time-space correlation information and output a disease grading result, and performing region division based on the grading result to determine differentiated medicament schemes. And preparing an environmental response type sustained release preparation, and carrying out targeted drug delivery according to a zoning scheme. The problems that in the prior art, disease diagnosis efficiency is low, grading subjectivity is high, and a space-time propagation rule cannot be captured are solved.

The present application provides a resin composition comprising at least a resin (A) which is a copolymer of ethylene and a vinyl monomer containing an oxygen atom, a carboxylic acid ester (B) having a linear or branched chain with a vapor pressure of 1.0 x 10 －4 Pa or more at 25°C, and an insect repellent (C) having a vapor pressure of 1.0 x 10 －4 Pa or more at 25°C, wherein the amount of the resin (A) is 10 to 87 mass%, the amount of the carboxylic acid ester (B) is 3 to 30 mass%, the amount of the insect repellent (C) is 10 to 60 mass%, and the mass ratio of the carboxylic acid ester (B) to the insect repellent (C) is 2:1 to 1:5, based on the total amount of the resin composition.

The invention belongs to the technical field of pharmacy, and particularly relates to a rhizoma phragmitis sustained release preparation for hyperuricemia and a preparation method of the rhizoma phragmitis sustained release preparation. The reed rhizome sustained release preparation for hyperuricemia is prepared from the following raw materials in parts by weight: 80 to 100 parts of reed rhizome extract, 160 to 200 parts of functionalized reed rhizome powder, 0.01 to 0.1 part of freeze-dried powder, 40 to 65 parts of quercetin and 30 to 50 parts of acrylic resin, the rhizoma phragmitis extract and quercetin cooperate to comprehensively regulate uric acid metabolism; due to the introduction of the freeze-dried powder, real-time visual monitoring of in-vivo drug distribution and drug release progress is realized, and the targeting affinity of the preparation with intestinal mucosa and joint parts can be improved, so that the blood uric acid level quickly tends to be stable and is maintained for a long time; after the colon target positioning sustained-release pellet and the quercetin quick-release pellet are mixed, the quick-release pellet can be quickly disintegrated and release quercetin to realize quick acid control, and the sustained-release pellet can accurately deliver drugs in the colon and continuously release active ingredients to realize long-acting acid stabilization.

The application discloses an oral preparation capable of improving 5-HT level in the brain and application thereof in improving insomnia, and belongs to the field of food science. The oral preparation uses starch and beta-cyclodextrin as nanoparticle carriers to wrap 5-HTP, can effectively control the release rate of 5-HTP, makes it slowly release in the gastrointestinal tract, and improves the defect that the half-life of 5-HTP is short. The preparation can significantly improve the content of 5-HT in the brain, and improve the metabolic kinetic characteristics of 5-HT, thereby effectively improving the insomnia symptoms. Experimental data shows that, compared with the traditional 5-HTP, the slow-release preparation has better bioavailability and longer brain drug efficacy duration. The innovative preparation not only has significant advantages in technology, but also opens up a new, safe and effective way for the treatment of 5-HT related nervous system diseases, and has important application value and research significance.

The invention discloses application of cimicifugin in preparation of a medicine for preventing or treating inner ear hair cell injury, and belongs to the technical field of biological medicine. According to the invention, it is found for the first time that a natural compound cimifugin has a definite inner ear hair cell protection effect. By inhibiting hair cell apoptosis and reducing hearing synapse loss and hearing nerve fiber injury, the cimicifugin effectively relieves hair cell injury and hearing function decline caused by cis-platinum and other drugs, noise exposure and aging. The protection mechanism is related to inhibition of activation of a pro-apoptosis signal. The preferred administration mode is local administration, especially delivery through a round window membrane, and the dosage form can be a solution, a suspension or a sustained release preparation. Cell, in-vitro hair cell tissue and animal model experiments prove that the cimicifugin can obviously relieve hair cell damage and improve the auditory function. The invention provides a new drug candidate scheme for preventing and treating sensorineural hearing loss, and has important clinical application value.

The invention belongs to the field of biological pharmacy, and particularly discloses application of evodiamine in inhibition of migration and invasion of gallbladder cancer cells and metastatic tumor growth. Aiming at the problems of poor drug targeting, high toxicity, easy drug resistance and the like in gallbladder cancer hepatic metastasis treatment, the invention provides various application forms of evodiamine: 1) an evodiamine single-drug sustained release preparation (PLGA or chitosan carrier) realizes long-acting sustained release through local intervention or intratumor injection; 2) the evodiamine liposome preparation (the ratio of DPPC to cholesterol is 3: 1, and the particle size is 80-150nm) can improve the enrichment rate of hepatic metastatic focus to 5.8% or above; (3) the evodiamine and chemotherapeutic drugs (oxaliplatin, 5-FU and the like) are combined to form a composition, and the synergy index is Cilt; 0.8, the toxicity of the system is obviously reduced; animal experiments show that the liver metastasis inhibition rate reaches 82.7% and the weight loss rate is only 10.5% when the liposome (3 mg / kg of evodiamine and 6 mg / kg of oxaliplatin) is combined, and a high-efficiency and low-toxicity solution is provided for gallbladder carcinoma metastasis.

This description relates to gastro-resistant controlled-release dosage forms comprising Compound (I): (see Formula) (I), or a pharmaceutically acceptable salt and / or solvate thereof, the pharmacokinetic properties of these dosage forms, and their preparation. The novel dosage forms described herein are useful for reducing the risk of QT prolongation in a subject and for treating a disorder in a subject in need, e.g., a subject diagnosed with schizophrenia, for example, in the treatment of negative symptoms in a subject diagnosed with schizophrenia who has the CYP2D6 EM genotype.

The present application provides a kind of tofacitinib citrate sustained-release preparation, which is composed of tablet core, sustained-release layer coating and color layer coating, and the sustained-release layer coating has drug release small holes. By adjusting the composition of osmotic pressure forming agent and its dosage ratio with sustained-release agent, further optimizing the composition and coating weight of sustained-release layer coating, not only the defect of slow dissolution rate after long-term storage when using sorbitol as osmotic pressure forming agent alone is avoided, but also the initial release rate of tofacitinib citrate sustained-release tablet is improved, and slow and sustained release can be maintained for 6 hours, the drug release is more complete, the blood drug concentration is kept at a uniform and stable level for a long time, the fluctuation of blood drug concentration during the interval of administration is reduced, the bioavailability is further improved, the adverse reactions are reduced, and the clinical efficacy and safety are protected.